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Abstract Imatinib (Glivec or Gleevec) potently inhibits
the tyrosine kinase activity of BCR-ABL, a constitutively
activated kinase, which causes chronic myelogenous leu-
kemia (CML). Here we report the first almost complete
backbone assignment of c-ABL kinase domain in complex
with imatinib.
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Biological context
Tyrosine kinases are important mediators in signal trans-
duction pathways and are tightly regulated by several
mechanisms. Aberrant activation of these enzymes may
lead to diseases, and mutations in kinase genes are impli-
cated in many forms of cancer (Greenman et al. 2007). A
number of tyrosine kinases are therefore attractive drug
targets for the discovery of inhibitors, which can modulate
the activity of these enzymes. The BCR-ABL fusion pro-
tein, having a constitutively activated Abelson (ABL)
kinase domain, is one such important drug target, which
has been clinically validated by imatinib (Glivec; Novartis
Pharma AG), an efficacious and well-tolerated treatment
for chronic myelogenous leukemia (CML) (Ren 2005).
Much structural knowledge on ABL-inhibitor complexes
has been generated using X-ray crystallography (Nagar
et al. 2002; Cowan-Jacob et al. 2007), but very little is
known about the solution structure and dynamics of ABL
kinase.
To enable NMR studies on the solution behavior of ABL
kinase, we have obtained backbone resonance assignment
of ABL kinase domain in complex with imatinib. The
selected construct of the ABL kinase domain (denoted here
as ABL, residues GAMDP-S229-S500) contains 277 resi-
dues and has a typical kinase bilobal structure, with the
N-terminal lobe containing b-sheets and the conserved
helix C, and the C-terminal lobe being mainly helical. At
the interface of the two lobes is the ATP-binding pocket,
which is also the binding site of most ABL inhibitors.
Methods and materials
Since ABL is not readily expressed in E. coli, we have
developed a protocol for the 13C/15N isotope labeling of the
ABL kinase catalytic domain in Baculovirus-infected
insect cells, either uniformly or selectively for certain
amino acid types (Strauss et al. 2003; Strauss et al. 2005).
Uniformly 13C,15N or selectively labeled samples
(Strauss et al. 2003; Strauss et al. 2005) of the ABL-
imatinib complex were prepared as 0.4 mM solutions in
250 ll (Shigemi microtubes) of buffer containing 95%
H2O, 5% D2O, 20 mM BisTris, 100 mM NaCl, 2 mM
EDTA, 3 mM DTT at pH 6.5 with an ABL:imatinib ratio
of 1:1. NMR spectra were recorded at 293 K on Bruker
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DRX 600 (cryo or room temperature probe) or DRX
800 MHz (cryoprobe) spectrometers. Due to the lack of
deuteration, the sensitivity of NMR experiments involving
13Cb or other side chain nuclei was very low. Therefore,
backbone assignments had to be performed with non-
TROSY versions of the HNCO, HNCA, HN(CO)CA
(Grzesiek and Bax 1992), and an 15N-edited 1H-1H
NOESY. The assignment was aided and verified by spectra
of a total of 15 selectively labeled samples that had 15N,
13Ca and 13C’ nuclei introduced specifically for certain
amino acid types (see supplementary material Table 1). All
NMR data were processed and analysed using the NMR-
Pipe (Delaglio et al. 1995) and NMRView (Johnson and
Blevins 1994) software suites. 1H, 15N and 13C are refer-
enced relative to the frequency of the 2H lock resonance of
water.
Extent of assignment and data deposition
The achieved assignments comprise 96% of all backbone
1HN, 15N, 13Ca and 13CO resonances, covering 254 of the
264 non-proline residues (Fig. 1). Unassigned residues
consist of the N-terminal glycine, seven residues within the
activation loop (consisting of residues D381-P402), and
H361. Line broadening of adjacent residues indicates that
most of the missing residues are broadened beyond
detection due to intermediate conformational exchange.
Despite the difficulty in observing the entire activation
loop, the assignments include at least 14 key residues
involved in ligand binding. The assignments have been
deposited in the BMRB (accession number 15488).
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Fig. 1 1HN-15N HSQC-TROSY (Pervushin et al. 1997) spectrum of
uniformly 15N-labeled ABL kinase domain-imatinib complex with
assignment information. An ‘e’ denotes unassigned We NH sidechain
resonances, Subpanels a, b and c show enlarged regions of the
respective rectangular boxes in the main spectrum
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